Monochromatic excimer light (308 nm) in the treatment of prurigo nodularis

  1. Rosita Saraceno1,
  2. Steven P. Nisticò1,
  3. Elisabetta Capriotti1,
  4. Catia De Felice1,
  5. Lesley E. Rhodes2,
  6. Sergio Chimenti1

Article first published online: 13 JAN 2008

DOI: 10.1111/j.1600-0781.2008.00318.x

Issue

Photodermatology, Photoimmunology & Photomedicine

Photodermatology, Photoimmunology & Photomedicine

Volume 24, Issue 1, pages 43–45, February 2008

Additional Information

How to Cite

Saraceno, R., Nisticò, S. P., Capriotti, E., De Felice, C., Rhodes, L. E. and Chimenti, S. (2008), Monochromatic excimer light (308 nm) in the treatment of prurigo nodularis. Photodermatology, Photoimmunology & Photomedicine, 24: 43–45. doi: 10.1111/j.1600-0781.2008.00318.x

Author Information

  1. 1

    Department of Dermatology, Policlinico Tor Vergata, University of Rome Tor Vergata, Rome, Italy, and

  2. 2

    Photobiology Unit, Dermatological Sciences, University of Manchester, Manchester, UK

*Correspondence: Rosita Saraceno, M.D., Department of Dermatology, Policlinico Tor Vergata, University of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy. Tel: +39 06 2690 2743 Fax: +39 06 2090 2742 e-mail: rositasaraceno@yahoo.it

  1. Conflicts of interest: None declared.

Publication History

  1. Issue published online: 13 JAN 2008
  2. Article first published online: 13 JAN 2008
  3. Accepted for publication: 21 July 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (138K)

Keywords:

  • 308 nm;
  • MEL;
  • prurigo nodularis

Summary

Three hundred and eight nanometre excimer light has been reported to be safe and effective in the treatment of chronic skin diseases, but the range of potential applications has not been fully explored. Our objective was to assess the efficacy of monochromatic excimer light (MEL) in the treatment of prurigo nodularis (PN). Eleven patients were enrolled in this pilot study. Patients were treated weekly and an average of eight sessions of MEL was given. Follow-up was 4 months. Partial or complete clinical and histological remission was observed in all patients who completed the study (81%).

View Full Article (HTML) Get PDF (138K)